| 0.8889 0.027 (3.12%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.19 | 1-year : | 1.39 |
| Resists | First : | 1.01 | Second : | 1.19 |
| Pivot price | 0.89  |
|||
| Supports | First : | 0.79 | Second : | 0.65 |
| MAs | MA(5) : | 0.88  |
MA(20) : | 0.85 |
| MA(100) : | 0.8 |
MA(250) : | 0.79 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 42 |
D(3) : | 51.5 |
| RSI | RSI(14): 57.7 |
|||
| 52-week | High : | 1.3 | Low : | 0.39 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NMTC ] has closed above bottom band by 47.5%. Bollinger Bands are 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.9 - 0.91 | 0.91 - 0.91 |
| Low: | 0.82 - 0.82 | 0.82 - 0.83 |
| Close: | 0.88 - 0.89 | 0.89 - 0.9 |
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Fri, 19 Dec 2025
With NeuroOne Medical Technologies Stock Surging, Have You Considered The Downside? - Trefis
Thu, 18 Dec 2025
NeuroOne Medical Technologies Corp (NMTC) Q4 2025 Earnings Call Highlights: Record Revenue ... - Yahoo Finance
Wed, 17 Dec 2025
Earnings call transcript: NeuroOne Q4 2025 sees revenue surge, stock rises - Investing.com
Wed, 17 Dec 2025
NeuroOne Medical Technologies Corporation Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com
Tue, 16 Dec 2025
Earnings To Watch: NeuroOne Medical Technologies Corp (NMTC) Reports Q4 2025 Result - Yahoo Finance
Thu, 11 Dec 2025
NeuroOne(R) to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Wednesday, December 17th at 8:30 a.m. Eastern Time - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 4.756e+007 (%) |
| Held by Institutions | 11.6 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.96e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -29.8 % |
| Operating Margin | -23.9 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -91.4 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 15 |
| Sales Per Share | 2.16071e+007 |
| EBITDA (p.s.) | 5.64286e+006 |
| Qtrly Earnings Growth | -0.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 3.55 |
| Dividend | 0 |
| Forward Dividend | 62430 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|